Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration

NCT00220805 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
DRUG: Albumin (Human) 25%, United States Pharmacopeia (USP)

Sponsor

Grifols Therapeutics LLC